This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $306,530 to Spinhance LLC to build, qualify, and clinically evaluate a novel cardiopulmonary imaging device. The device will enable continuous administration of the FDA-approved magnetic resonance imaging (MRI) contrast agent hyperpolarized xenon-129 (HPX), paired with physiological monitoring, to support a new paradigm for functional lung imaging that is accessible to all patients. The project aims to design an automatic, MRI-compatible, piston-based syringe pump system that can respond to subject breathing dynamics, synchronize HPX delivery with MRI data, heartbeat, and exhaled gas concentrations, without requiring patient compliance with breathing maneuvers. This initial phase of the project also includes demonstrating the feasibility of dynamic lung HPX MRI in a small pilot study to inform key device validation activities in a subsequent phase.
Generated 3/25/25, 4:21 AM